Cargando…
Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer
BACKGROUND: Lysosomal cysteine protease cathepsin V has previously been shown to exhibit elevated expression in breast cancer tissue and be associated with distant metastasis. Research has also identified that cathepsin V expression is elevated in tumour tissues from numerous other malignancies, but...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726886/ https://www.ncbi.nlm.nih.gov/pubmed/33298139 http://dx.doi.org/10.1186/s13058-020-01376-6 |
_version_ | 1783620972070305792 |
---|---|
author | Sereesongsaeng, Naphannop McDowell, Sara H. Burrows, James F. Scott, Christopher J. Burden, Roberta E. |
author_facet | Sereesongsaeng, Naphannop McDowell, Sara H. Burrows, James F. Scott, Christopher J. Burden, Roberta E. |
author_sort | Sereesongsaeng, Naphannop |
collection | PubMed |
description | BACKGROUND: Lysosomal cysteine protease cathepsin V has previously been shown to exhibit elevated expression in breast cancer tissue and be associated with distant metastasis. Research has also identified that cathepsin V expression is elevated in tumour tissues from numerous other malignancies, but despite this, there has been limited examination of the function of this protease in cancer. Here we investigate the role of cathepsin V in breast cancer in order to delineate the molecular mechanisms by which this protease contributes to tumourigenesis. METHODS: Lentiviral transductions were used to generate shRNA cell line models, with cell line validation undertaken using RQ-PCR and Western blotting. Phenotypic changes of tumour cell biology were examined using clonogenic and invasion assays. The relationship between GATA3 expression and cathepsin V was primarily analysed using Western blotting. Site-directed mutagenesis was used to generate catalytic mutant and shRNA-resistant constructs to confirm the role of cathepsin V in regulating GATA3 expression. RESULTS: We have identified that elevated cathepsin V expression is associated with reduced survival in ER-positive breast cancers. Cathepsin V regulates the expression of GATA3 in ER-positive breast cancers, through promoting its degradation via the proteasome. We have determined that depletion of cathepsin V results in elevated pAkt-1 and reduced GSK-3β expression, which rescues GATA3 from proteasomal degradation. CONCLUSIONS: In this study, we have identified that cysteine protease cathepsin V can suppress GATA3 expression in ER-positive breast cancers by facilitating its turnover via the proteasome. Therefore, targeting cathepsin V may represent a potential therapeutic strategy in ER-positive breast cancers, by restoring GATA3 protein expression, which is associated with a more favourable clinical outcome. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13058-020-01376-6. |
format | Online Article Text |
id | pubmed-7726886 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77268862020-12-10 Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer Sereesongsaeng, Naphannop McDowell, Sara H. Burrows, James F. Scott, Christopher J. Burden, Roberta E. Breast Cancer Res Research Article BACKGROUND: Lysosomal cysteine protease cathepsin V has previously been shown to exhibit elevated expression in breast cancer tissue and be associated with distant metastasis. Research has also identified that cathepsin V expression is elevated in tumour tissues from numerous other malignancies, but despite this, there has been limited examination of the function of this protease in cancer. Here we investigate the role of cathepsin V in breast cancer in order to delineate the molecular mechanisms by which this protease contributes to tumourigenesis. METHODS: Lentiviral transductions were used to generate shRNA cell line models, with cell line validation undertaken using RQ-PCR and Western blotting. Phenotypic changes of tumour cell biology were examined using clonogenic and invasion assays. The relationship between GATA3 expression and cathepsin V was primarily analysed using Western blotting. Site-directed mutagenesis was used to generate catalytic mutant and shRNA-resistant constructs to confirm the role of cathepsin V in regulating GATA3 expression. RESULTS: We have identified that elevated cathepsin V expression is associated with reduced survival in ER-positive breast cancers. Cathepsin V regulates the expression of GATA3 in ER-positive breast cancers, through promoting its degradation via the proteasome. We have determined that depletion of cathepsin V results in elevated pAkt-1 and reduced GSK-3β expression, which rescues GATA3 from proteasomal degradation. CONCLUSIONS: In this study, we have identified that cysteine protease cathepsin V can suppress GATA3 expression in ER-positive breast cancers by facilitating its turnover via the proteasome. Therefore, targeting cathepsin V may represent a potential therapeutic strategy in ER-positive breast cancers, by restoring GATA3 protein expression, which is associated with a more favourable clinical outcome. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13058-020-01376-6. BioMed Central 2020-12-09 2020 /pmc/articles/PMC7726886/ /pubmed/33298139 http://dx.doi.org/10.1186/s13058-020-01376-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Sereesongsaeng, Naphannop McDowell, Sara H. Burrows, James F. Scott, Christopher J. Burden, Roberta E. Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer |
title | Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer |
title_full | Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer |
title_fullStr | Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer |
title_full_unstemmed | Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer |
title_short | Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer |
title_sort | cathepsin v suppresses gata3 protein expression in luminal a breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726886/ https://www.ncbi.nlm.nih.gov/pubmed/33298139 http://dx.doi.org/10.1186/s13058-020-01376-6 |
work_keys_str_mv | AT sereesongsaengnaphannop cathepsinvsuppressesgata3proteinexpressioninluminalabreastcancer AT mcdowellsarah cathepsinvsuppressesgata3proteinexpressioninluminalabreastcancer AT burrowsjamesf cathepsinvsuppressesgata3proteinexpressioninluminalabreastcancer AT scottchristopherj cathepsinvsuppressesgata3proteinexpressioninluminalabreastcancer AT burdenrobertae cathepsinvsuppressesgata3proteinexpressioninluminalabreastcancer |